Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Julphar inaugurates manufacturing facility in Ethiopia
Julphar said it has invested ETB170m ($9.13m) in constructing new facility, which was built in conjunction with its local Ethiopian partner, Medtech, and occupies 40,000 ft² space. The
Julphar said it has invested ETB170m ($9.13m) in constructing new facility, which was built in conjunction with its local Ethiopian partner, Medtech, and occupies 40,000 ft² space. The
A Gilead subsidiary acquired all YM’s outstanding common shares as per the terms of a plan of arrangement. Thus, YM has become a wholly-owned subsidiary of Gilead. YM
Olivenol plus line of organic products for health and wellness features olive polyphenols and hydroxytyrosol. CreAgri CEO and president Roberto Crea said, "Starting today with Florida and rapidly
The company said the new plant is expected to increase production capacity by 50%, bringing total annual output to about two billion ampoules, vials, syringes, and cartridges. The
Featuring an easy to use, interactive dashboard, the Vortex tool allows the manipulation of vast amounts of data points including chemical structures, using just a standard PC or
The collaboration will focus on preclinical and clinical development of therapeutic peptide, developed by Pergamum, with both anti-infective and anti-inflammatory properties. Development activities will be carried out at
Avanir completed first of a two-stage pharmacokinetic study of AVP-786 in healthy subjects According to the interim data, a formulation of AVP-786 has a similar pharmacokinetic, safety and
The new software uses TLC data from 2 to 10 different TLC and includes step gradient optimization feature that helps to estimate where the individual sample components will
The studies compared the pharmacokinetic activity of rFVIIIFc for hemophilia A and rFIXFc for hemophilia B to existing standard therapies. Data from phase 3 registrational studies demonstrated that
The ultrasound contrast agent Definity is indicated for use in patients with suboptimal echocardiograms to opacify the left ventricular chamber and to recover the delineation of the left